Active constituent–target network analysis revealed that ACT and FA target molecules involved in pathways considered essential for the treatment of depression, including metabolic pathways, MAPK signaling, IL‐17 signaling, neurotrophic signaling, neurotransmitter synthesis, cAMP signaling, and inflammatory cytokine pathways (Figure3A–D). Here, IL17A is linked to depressive symptom measurement.